Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: A euglycemic-hyperinsulinemic clamp study

Diabetes

Volumn 51, Issue 9, 2002, Pages 2677-2683

  Pospisilik, John A ^a   Stafford, Sara G ^a   Demuth, Hans Ulrich ^b   McIntosh, Christopher H S ^a   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROBIODRUG AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENZYME SPECIFICITY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; HYPERINSULINEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

EID: 0036724721     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.9.2677     Document Type: Article

References (50)

1. The incretin concept today
2. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling
3. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
4. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
5. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells
6. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells
7. Glucose-dependent insulinotropic polypeptide (GIP) stimulates cell proliferation and promotes survival of β-(INS-1)-cells
8. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
9. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
10. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-l-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
11. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
12. Actions of GIP
13. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
14. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats
15. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: A novel kinetic approach
16. Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance
17. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
18. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
19. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1(7-36 anfide) antide) concentrations and improves oral glucose tolerance in obese Zucker rats
20. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
21. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats
22. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats
23. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
24. Recent developments in inhibiting cysteine and serine proteases
25. Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas
26. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin camp
27. Influences of glucose loading and injected insulin on hepatic glucose output
28. Measurement of glucose concentrations in rats: Differences between glucose meter and plasma laboratory results
29. Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats
30. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor
31. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima fatty rats, an animal model for non-insulin-dependent diabetes mellitus
32. Noninsulin-dependent animal models of diabetes mellitus
33. The effect of CP 68722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats
34. JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models
35. Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat
36. One week continuous infusion of GLP-1 (7-37) improves glycemic control in NIDDM
37. Near normalisation of diurnal glucose concentrations by continuous administrations of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
38. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
39. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells
40. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs
41. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes
42. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus
43. Kinetic study of the processing by dipeptidyl-peptidase IV/CD 26 of neuropeptides involved in insulin secretion
44. Metabolism of glucagon by dipeptidyl peptidase IV (CD26)
45. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon: Characterization of glucagon degradation products and DPIV-resistant analogs
46. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides
47. Glucagon receptors on human islet cells contribute to glucose competence of insulin release
48. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
49. Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes
50. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle